Identify biomarkers to pair patients with targeted therapies.1
IVDR certified liquid CDx approvals for NSCLC as well as for targeted breast cancer therapy with ESR1 mutations.1
CDx, companion diagnostic; NSCLC, non-small cell lung cancer.
TAGRISSO® is a registered trademark of the AstraZeneca group of companies.
RYBREVANT® is a registered trademark of Janssen Biotech, Inc.
LUMAKRASâ„¢ is a trademark of Amgen Inc.
ORSERDUâ„¢ is a trademark of Stemline Therapeutics, a Menarini Group Company.
Product availability may vary depending on region.